/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Better Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.036 0.2743(27.43%) BTTX at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 0.0423
Highest Today 0.095
Today’s Open 0.0716
Prev. Close 0.035
52 Week High 1.61
52 Week Low 0.03
Day’s Range: Low 0.0423 High 0.095
52-Week Range: Low 0.03 High 1.61
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Mmcap International Inc. Spc 2.90

Vanguard Group Inc 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.36

Geode Capital Management, LLC 0.20

BlackRock Inc 0.16

Fidelity Extended Market Index 0.15

Capital Investment Advisory Services, LLC 0.13

Fidelity Nasdaq Composite Index 0.13

State Street Corporation 0.11

BlackRock Extended Mkt Composite 0.10

BlackRock Extended Equity Market K 0.09

Millennium Management LLC 0.07

iShares Micro-Cap ETF 0.05

CI Private Wealth LLC 0.05

Citadel Advisors Llc 0.05

Tower Research Capital LLC 0.04

Group One Trading, LP 0.03

Northern Trust Corp 0.03

Ameriprise Financial Inc 0.03

XTX Topco Ltd 0.03

Fidelity Series Total Market Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

Extended Equity Market Fund M 0.01

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Spartan Total Market Index Pool E 0.01

SSgA U.S. Total Market Index Strategy 0.00

1290 VT Micro Cap K 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Aspire Private Capital, LLC 0.00

Royal Bank of Canada 0.00

Wells Fargo & Co 0.00

PSI Advisors, LLC 0.00

Farallon Capital Management, L.L.C. 0.00

JPMorgan Chase & Co 0.00

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1.91 M

PB Ratio 2.289

PE Ratio 0.0

Enterprise Value 9.67 M

Total Assets 22.94 M

Volume 204525202

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:8000 0.0M, FY19:18000 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-674000 -0.7M, FY19:-880000 -0.9M

Annual Net worth FY23:-31573000 -31.6M, FY22:-39760000 -39.8M, FY21:-40335000 -40.3M, FY20:-6387000 -6.4M, FY19:-5795000 -5.8M

Quarterly Revenue Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M, Q4/2022:0 0.0M, Q3/2022:0 0.0M

Quarterly Profit Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M, Q4/2022:null 0.0M, Q3/2022:null 0.0M

Quarterly Net worth Q3/2023:-5862000 -5.9M, Q2/2023:-7589000 -7.6M, Q1/2023:-9357000 -9.4M, Q4/2022:-8765000 -8.8M, Q3/2022:-11405000 -11.4M

Fund house & investment objective

Company Information Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Organisation Biotechnology

Employees 54

Industry Biotechnology

CEO Mr. Frank L. Karbe

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow